HRP20040648B1 - Ultrapure oral fludara formulation with a fast releasing active substance - Google Patents

Ultrapure oral fludara formulation with a fast releasing active substance

Info

Publication number
HRP20040648B1
HRP20040648B1 HRP20040648A HRP20040648B1 HR P20040648 B1 HRP20040648 B1 HR P20040648B1 HR P20040648 A HRP20040648 A HR P20040648A HR P20040648 B1 HRP20040648 B1 HR P20040648B1
Authority
HR
Croatia
Prior art keywords
fludara
ultrapure
oral
formulation
active substance
Prior art date
Application number
Other languages
English (en)
Inventor
Wolfgang Heil
Ulf Tilstam
Ralph Lipp
Johannes-Wilhelm Tack
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7711168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040648(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of HRP20040648A2 publication Critical patent/HRP20040648A2/hr
Publication of HRP20040648B1 publication Critical patent/HRP20040648B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HR20040648 2001-12-20 2004-07-15 Ultrapure oral fludara formulation with a fast releasing active substance HRP20040648B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (de) 2001-12-20 2001-12-20 Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
PCT/EP2002/013252 WO2003053418A1 (de) 2001-12-20 2002-11-25 Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes

Publications (2)

Publication Number Publication Date
HRP20040648A2 HRP20040648A2 (en) 2004-10-31
HRP20040648B1 true HRP20040648B1 (en) 2012-11-30

Family

ID=7711168

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040648 HRP20040648B1 (en) 2001-12-20 2004-07-15 Ultrapure oral fludara formulation with a fast releasing active substance

Country Status (30)

Country Link
US (1) US7148207B2 (xx)
EP (1) EP1455760B1 (xx)
JP (2) JP2005519043A (xx)
KR (1) KR100884685B1 (xx)
CN (1) CN1306929C (xx)
AR (1) AR037965A1 (xx)
AT (1) ATE303797T1 (xx)
AU (1) AU2002349043B2 (xx)
BR (1) BR0215265A (xx)
CA (1) CA2471396A1 (xx)
DE (2) DE10164510A1 (xx)
DK (1) DK1455760T3 (xx)
EC (1) ECSP045185A (xx)
ES (1) ES2248624T3 (xx)
HK (1) HK1077741A1 (xx)
HR (1) HRP20040648B1 (xx)
IL (2) IL162555A0 (xx)
JO (1) JO2363B1 (xx)
MX (1) MXPA04006005A (xx)
NO (1) NO20043063L (xx)
NZ (1) NZ533701A (xx)
PE (1) PE20030639A1 (xx)
RS (1) RS50398B (xx)
RU (1) RU2318496C2 (xx)
SA (1) SA03240091B1 (xx)
TW (1) TWI255187B (xx)
UA (1) UA78741C2 (xx)
UY (1) UY27596A1 (xx)
WO (1) WO2003053418A1 (xx)
ZA (1) ZA200405735B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201190243A1 (ru) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани Стабильная фармацевтическая композиция флударабина фосфата
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
CN101947208B (zh) * 2010-10-09 2012-05-23 江苏奥赛康药业股份有限公司 一种供注射用的磷酸氟达拉滨组合物及其制备方法
CN102091046B (zh) * 2011-02-12 2012-07-18 海南锦瑞制药股份有限公司 一种磷酸氟达拉滨冻干粉针剂及其制备方法
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN111423458A (zh) * 2020-04-29 2020-07-17 东南大学 磷酸氟达拉滨杂质h对照品的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (de) * 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier
US5110919A (en) * 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
FR2701027B1 (fr) * 1993-02-01 1997-07-18 Warner Lambert Co Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate.
DE19543052A1 (de) 1995-11-06 1997-05-07 Schering Ag Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
SK283475B6 (sk) * 1997-12-11 2003-08-05 Schering Aktiengesellschaft Spôsob výroby lítnych, sodných, draselných, vápenatých a horečnatých solí fludarabín-fosfátu, spôsob čistenia pri výrobe fludarabín-fosfátu a fludarabín-fosfát s čistotou najmenej 99,5 %
CN1237958C (zh) 1998-06-11 2006-01-25 法玛西雅厄普约翰美国公司 一种非缓释的、非咀嚼的药物片剂组合物
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
WO2001014348A1 (en) 1999-08-20 2001-03-01 The Scripps Research Institute Formation of heterocycles
EP1175220B1 (en) 1999-12-08 2005-04-27 Pharmacia Corporation Nanoparticulate eplerenone compositions
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
EP1237555A2 (en) * 1999-12-16 2002-09-11 PHARMACIA & UPJOHN COMPANY Implant composition containing melengestrol acetate and trenbolone acetate
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets

Also Published As

Publication number Publication date
IL162555A (en) 2008-03-20
UA78741C2 (en) 2007-04-25
JP2005519043A (ja) 2005-06-30
RU2318496C2 (ru) 2008-03-10
TWI255187B (en) 2006-05-21
HRP20040648A2 (en) 2004-10-31
ZA200405735B (en) 2006-01-25
SA03240091B1 (ar) 2006-11-25
KR20040073501A (ko) 2004-08-19
EP1455760A1 (de) 2004-09-15
BR0215265A (pt) 2004-12-07
RS50398B (sr) 2009-12-31
AU2002349043B2 (en) 2007-08-16
AU2002349043A1 (en) 2003-07-09
US7148207B2 (en) 2006-12-12
AR037965A1 (es) 2004-12-22
MXPA04006005A (es) 2004-09-27
RU2004122479A (ru) 2005-05-20
CN1306929C (zh) 2007-03-28
IL162555A0 (en) 2005-11-20
ES2248624T3 (es) 2006-03-16
JP2006137771A (ja) 2006-06-01
JO2363B1 (en) 2006-12-12
RS53304A (xx) 2006-10-27
KR100884685B1 (ko) 2009-02-18
EP1455760B1 (de) 2005-09-07
CN1617713A (zh) 2005-05-18
ATE303797T1 (de) 2005-09-15
CA2471396A1 (en) 2003-07-03
DE10164510A1 (de) 2003-07-10
NZ533701A (en) 2006-03-31
NO20043063L (no) 2004-07-19
HK1077741A1 (en) 2006-02-24
UY27596A1 (es) 2003-07-31
DK1455760T3 (da) 2006-01-02
TW200305428A (en) 2003-11-01
PE20030639A1 (es) 2003-08-28
PL370792A1 (en) 2005-05-30
DE50204203D1 (de) 2005-10-13
US20030176391A1 (en) 2003-09-18
ECSP045185A (es) 2004-08-27
WO2003053418A1 (de) 2003-07-03

Similar Documents

Publication Publication Date Title
GB0104786D0 (en) Active Matrix Device
EG23943A (en) Flash-melt oral dosage formulation
EP1434601A4 (en) INSULIN PREPARATIONS ENCAPSULATED IN LIPOSOMES
SI1272167T1 (sl) Dozirna formulacija, ki vsebuje ropinirol, s hidrofilnim/lipofilnim polimernimm matriksom
GB0100407D0 (en) Formulation
GB0014074D0 (en) Active matrix array devices
AUPQ676800A0 (en) Dental device
SG112858A1 (en) Polymer compound and polymer light-emitting device using the same
AU2002352865A1 (en) Ball grid array package
EP1455675A4 (en) MATERIAL DENTAL CONTACT SYSTEM
GB0000891D0 (en) Formulation
GB0127069D0 (en) Imaging elements with nanocomposite containing supports
HUP0500638A3 (en) Flashmelt oral dosage formulation
GB0103761D0 (en) Agrochemical formulation
HRP20040648B1 (en) Ultrapure oral fludara formulation with a fast releasing active substance
PL367280A1 (en) Agrochemical formulations
PL375834A1 (en) Chronotherapeutic diltiazem formulations and the administration thereof
HUP0001430A3 (en) Manufacturing device
PL366067A1 (en) Oxayolidinone tablet formulation
GB0125492D0 (en) Formulation
MXPA03007272A (es) Formulacion de medicamento que contiene agonista muscarinico.
GB0013400D0 (en) A formulation
IL147063A0 (en) Pesticidal formulation
GB0031727D0 (en) Head-band locking device
GB2375048B (en) Formulation

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

PPPP Transfer of rights

Owner name: ALCAFLEU MANAGEMENT GMBH & CO. KG., DE

PNAN Change of the applicant name, address/residence

Owner name: ALCAFLEU MANAGEMENT GMBH & CO. KG., DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20121010

Year of fee payment: 11

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20130715